Dr Reddy's Q2 Net Profit Falls 36% Amid North America Sales Decline
Dr Reddy's Laboratories reported a 36% year-on-year decline in Q2 net profit to around Rs 913-925 crore, with revenue falling about 1.5% to approximately Rs 8,671 crore. The profit drop was mainly due to lower lenalidomide sales in North America, where revenue fell 23%. However, India and emerging markets saw revenue growth of 17% and 24%, respectively. Sequentially, profit more than doubled from Q1, aided by easing semaglutide-related provisions. The company emphasized ongoing focus on core business growth, strategic investments, and upcoming semaglutide launches.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (51/100). Lens Score 42/100.
Outlets measured: businessstandard, news18, economictimes, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 23 Oct, 12:34 pm. Other outlets followed.